Coronavirus treatment: Health ministry revises remdesivir dosage for Covid-19 patients

In the latest protocol, the Ministry has described the use of investigational therapies - Remdesivir, Convalescent plasma, Tocilizumab, and Hydroxychloroquine on coronavirus patients

ANI
Updated4 Jul 2020, 06:33 AM IST
The Union Health Ministry has revised the dosage of remdesivir, being administered to hospitalized COVID-19 patients from the earlier six-days to five-day treatment course.
The Union Health Ministry has revised the dosage of remdesivir, being administered to hospitalized COVID-19 patients from the earlier six-days to five-day treatment course.(AFP)

New Delhi: The Union Health Ministry on Friday has revised the dosage of the antiviral drug--remdesivir, being administered to hospitalized COVID-19 patients from the earlier six-days to five-day treatment course.

According to the Health Ministry, remdesivir drug is only for restricted emergency use on patients with moderate disease (those on oxygen support). The drug can not be administered to a pregnant or lactating mother and children below the age of 12 years. Also, the drug is not recommended to a patient with severe renal impairment and a high level of liver enzymes.

The Central Health Ministry has issued a fresh clinical management protocol for COVID-19 patients on Friday. In the latest protocol, the ministry has informed the dosage of remdesivir should be-- 200 mg IV on day 1 followed by 100 mg IV daily for 4 days (5 days in total). However, in the previous clinical protocol issued on June 13, the Health Ministry stated that the patient has to be administered with 200 mg IV on day 1 followed by 100 mg IV daily for 5 days, that was, 6 days in total.

Further, the use of these drugs is subjected to limited availability in the country as of now. Currently, these drugs should only be used in a defined subgroup of patients.

In the latest protocol, the Ministry has described the use of investigational therapies--Remdesivir, Convalescent plasma, Tocilizumab, and Hydroxychloroquine (HCQ) on coronavirus patients.

The use of anti-malaria drug HCQ has been recommended for early use in the disease course as possible to achieve any meaningful effects and should be avoided in patients with severe disease. However, the use of Tocilizumab drug as an off-label application may be considered in patients with moderate disease with progressively increasing oxygen requirements.

Catch all the Business News , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.

MoreLess
First Published:4 Jul 2020, 06:33 AM IST
Business NewsNewsIndiaCoronavirus treatment: Health ministry revises remdesivir dosage for Covid-19 patients

Get Instant Loan up to ₹10 Lakh!

  • Employment Type

    Most Active Stocks

    ITC share price

    482.25
    09:31 AM | 6 NOV 2024
    2.2 (0.46%)

    Infosys share price

    1,779.65
    09:31 AM | 6 NOV 2024
    25.85 (1.47%)

    Larsen & Toubro share price

    3,597.25
    09:31 AM | 6 NOV 2024
    21.85 (0.61%)

    Tata Steel share price

    150.60
    09:31 AM | 6 NOV 2024
    -1.7 (-1.12%)
    More Active Stocks

    Market Snapshot

    • Top Gainers
    • Top Losers
    • 52 Week High

    Mankind Pharma share price

    2,795.85
    09:20 AM | 6 NOV 2024
    81.45 (3%)

    Suven Pharmaceuticals share price

    1,321.35
    09:20 AM | 6 NOV 2024
    -11.75 (-0.88%)

    National Aluminium Company share price

    229.85
    09:20 AM | 6 NOV 2024
    -5.15 (-2.19%)
    More from 52 Week High

    Hindustan Zinc share price

    521.90
    09:20 AM | 6 NOV 2024
    -37.55 (-6.71%)

    Triveni Engineering & Indus share price

    401.50
    09:20 AM | 6 NOV 2024
    -15.75 (-3.77%)

    Titan Company share price

    3,147.60
    09:20 AM | 6 NOV 2024
    -85.45 (-2.64%)

    National Aluminium Company share price

    229.85
    09:20 AM | 6 NOV 2024
    -5.15 (-2.19%)
    More from Top Losers

    CCL Products India share price

    712.10
    09:20 AM | 6 NOV 2024
    43.7 (6.54%)

    GAIL India share price

    207.30
    09:20 AM | 6 NOV 2024
    10.9 (5.55%)

    Kaynes Technology India share price

    5,552.95
    09:20 AM | 6 NOV 2024
    236.25 (4.44%)

    Supreme Industries share price

    4,543.10
    09:20 AM | 6 NOV 2024
    175.75 (4.02%)
    More from Top Gainers

    Recommended For You

      More Recommendations

      Gold Prices

      • 24K
      • 22K
      Bangalore
      80,255.000.00
      Chennai
      80,261.000.00
      Delhi
      80,413.000.00
      Kolkata
      80,265.000.00

      Fuel Price

      • Petrol
      • Diesel
      Bangalore
      102.92/L0.00
      Chennai
      100.80/L0.00
      Kolkata
      104.95/L0.00
      New Delhi
      94.77/L0.00

      Popular in News

        HomeMarketsPremiumInstant LoanMint Shorts